As of November 6, 2026, Research Alliance Corp IV has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 14, 2026 (Form 8-K, July 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Research Alliance Corp IV? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Research Alliance Corp IV reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-14. Every row below is cited to the filing it comes from, and this page adds each new change as Research Alliance Corp IV files it.
Also on the record for Research Alliance Corp IV
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 21, 2026 | Stake report, Schedule 13D, by Research Alliance Holdings IV LLC | 17% of the class | 5%+ stakes | Source |
| July 21, 2026 | Stake report, Schedule 13G, by Trails Edge Capital Partners, LP | 5.5% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G, by BVF PARTNERS L P/IL | 6.4% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G, by Commodore Capital LP | 5.5% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G, by Perceptive Advisors LLC | 7.7% of the class | 5%+ stakes | Source |
| July 13, 2026 | IPO filing, Form 424B4 | $10 a share | IPO filings | Source |
| July 8, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 8, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Research Alliance Corp IV now and the warning signs.
Free to see. No signup.
Keep reading
More on Research Alliance Corp IV and the records around it.
Research Alliance Corp IV elsewhere on the record
- 5%+ stake filings Jul 2026
Companies that share a holder
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch Research Alliance Corp IV
Get an email when Research Alliance Corp IV files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Research Alliance Corp IV?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Research Alliance Corp IV: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Research Alliance Corp IV covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-14 | Reported | not named in the filing | 8-K, 2026-07-14 |
New leaders reset buying decisions — get the Full Report on Research Alliance Corp IV: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Research Alliance Corp IV, with the record behind each one.
Find candidates like senior executive at Research Alliance Corp IVEvery change, in the filing's words
Reported
On July 10, 2026, and in connection with the IPO, Alan Musso and John Maslowskiwere appointed to the board of directors of the Company (the " Board ").
- Effective July 10, 2026, (i) each of Mr. Musso and Mr. Maslowski was appointed to the Board's Audit Committee, with Mr. Musso serving as its chair; (ii) each of Matthew Hammond, Mr. Maslowski, and Mr. Musso was appointed to the Board's Nominating Committee, with Mr. Maslowski serving as its chair; and (iii) each of Mr. Maslowski and Mr. Musso was appointed to the Board's Compensation Committee, with Mr. Maslowski serving as its chair.
- In June 2026, the Sponsor transferred 30,000 Class B ordinary shares of the Company, par value $0.0001 per share ("Class B ordinary shares"), to each of Mr. Musso and Mr. Maslowski as compensation for his service as a director of the Company.
Tools for this story
Each opens in a new tab, filled in for Research Alliance Corp IV. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.